Paper: New Payment & Funding Approaches for ATMPs

The recent years have seen a number of high-end innovative therapies becoming accessible to patients in Europe. These products offer groundbreaking new opportunities to patients living with rare diseases or cancer, with the capacity of often one-time disease-modifying and potentially curative treatments.

This new generation of therapies calls for a new paradigm of care, where it is necessary to consider the affordability issues for health systems, from a long-term perspective.

As elaborated in its Position Paper on New Payment & Funding Approaches for ATMPs, EUCOPE calls for a coherent approach with the scientific community, treatment centres, payers and manufacturers to define key parameters, criteria and assessment over time to establish outcome-based models, increase the use of Real-World Evidence and set up specific ATMPs funds within the healthcare systems.